Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic PeptideRiaz Jannoo(University College London), Venkateswarlu Kanamarlapudi(Swansea University)CancersMay 16, 202310.3390/cancers15102772Cited by 7SaveCiteExport RISWatch citationsRelated PapersExchange Factor EFA6R Requires C-terminal Targeting to the Plasma Membrane to Promote Cytoskeletal Rearrangement through the Activation of ADP-ribosylation Factor 6 (ARF6)|Journal of Biological Chemistry|2014|26